Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer.
Matthew LoftSheau Wen LokRichard De BoerLaeeq MalikSally GreenbergBelinda YeoAngelyn AntonMichelle NottageVanessa WongLouise NottIan M CollinsJavier TorresFrances BarnettJanine M LombardPeter GibbsLucy GatelyPublished in: Breast cancer research and treatment (2023)
The addition of ET to first-line dual anti-HER2 therapy post chemotherapy in patients with HER2 + /HR + MBC was associated with major gains in PFS and OS with no safety concerns evident. Further studies of this combination are justified, along with studies of how best to integrate other agents that are active in this patient subset, including CDK4/6 inhibitors.